Fig. 5
Role of BiP in nuclear NRF1 and ABCA1 expression under high cholesterol condition. a–e UCB-MSCs were pretreated BiP inhibitor, Ver155008 (10 μM) prior to cholesterol treatment (200 μM, 24 h). a Immunocytochemistry was conducted with NRF1 (green), BiP (red) specific antibodies and DAPI (blue), and then visualized by SRRF imaging system. Scale bar was set as 8 μm (magnification × 1000). The co-localization of BiP and NRF1, nuclear translocation of NRF1 were analyzed with Fiji software. (n = 7). b The expression level of ABCA1 was quantified with western blotting (n = 5). c The concentration of the cellular cholesterol was measured with cholesterol quantification kit (n = 5). d Cells were incubated with CM-H2DCFDA and relative fluorescence units (RFU) were measured by luminometer (n = 5). e Cell viability was measured by trypan blue exclusion assay (n = 5). All blot and images are representative and quantitative data are presented as a mean ± standard error of the mean. *p < 0.05 vs control, #p < 0.05 vs cholesterol